相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey et al.
INVESTIGATIONAL NEW DRUGS (2012)
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
E. Normant et al.
ONCOGENE (2011)
Treatment of HER2-overexpressing breast cancer
J. Baselga
ANNALS OF ONCOLOGY (2010)
17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells
Panagiotis K. Karkoulis et al.
BMC CANCER (2010)
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
James R. Porter et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar et al.
EUROPEAN JOURNAL OF CANCER (2010)
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
Martin Kaiser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer
Dario C. Altieri
FUTURE ONCOLOGY (2010)
Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours
Gu Hyun Kang et al.
HISTOPATHOLOGY (2010)
Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions
Yasutomo Suzuki et al.
INTERNATIONAL JOURNAL OF UROLOGY (2010)
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
Morassa Mohseni et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Heat Shock Protein 90: Inhibitors in Clinical Trials
Marco A. Biamonte et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
Bin Peng et al.
MOLECULAR CANCER (2010)
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
J. E. Lancet et al.
LEUKEMIA (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors ?
Frank Bergmann et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
X. Wu et al.
BRITISH JOURNAL OF CANCER (2009)
The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas
Jeremy S. Abramson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells
Eleonora Costantino et al.
CANCER LETTERS (2009)
How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer?
Yohannes Mebratu et al.
CELL CYCLE (2009)
17 AAG for HSP90 Inhibition in Cancer - From Bench to Bedside
Saad Z. Usmani et al.
CURRENT MOLECULAR MEDICINE (2009)
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
Britt Erika Hanson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis
Wooin Lee et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Heat shock protein inhibitors and vaccines as new agents in cancer treatment
Eleni M. Karapanagiotou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Targeting Heat Shock Protein 90 with Non-Quinone Inhibitors: A Novel Chemotherapeutic Approach in Human Hepatocellular Carcinoma
Marco Breinig et al.
HEPATOLOGY (2009)
Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial
Remi A. Nout et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
Barbro Eriksson et al.
NEUROENDOCRINOLOGY (2009)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Eloisi Caldas-Lopes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The Hsp90 molecular chaperone: an open and shut case for treatment
Laurence H. Pearl et al.
BIOCHEMICAL JOURNAL (2008)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit et al.
CLINICAL CANCER RESEARCH (2008)
Heat shock protein 90 inhibition in lung cancer
Takeshi Shimamura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Dongweon Song et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Regulation of tumor cell mitochondrial Homeostasis by an organelle-specific Hsp90 chaperone network
Byoung Heon Kang et al.
CELL (2007)
ER chaperones in mammalian development and human diseases
Min Ni et al.
FEBS LETTERS (2007)
Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition
Michael Burkitt et al.
MOLECULAR CARCINOGENESIS (2007)
High HSP90 expression is associated with decreased survival in breast cancer
Elah Pick et al.
CANCER RESEARCH (2007)
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Kathrin Zitzmann et al.
NEUROENDOCRINOLOGY (2007)
Resection of pancreatic neuroendocrine tumors - Results of 70 cases
Kevork K. Kazanjian et al.
ARCHIVES OF SURGERY (2006)
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
Jie Ge et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Akt induces β-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity
S Fatrai et al.
DIABETES (2006)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
OM Grbovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The molecular genetics of gastroenteropancreatic neuroendocrine tumors
MN Zikusoka et al.
CANCER (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
The HSP90 family of genes in the human genome: Insights into their divergence and evolution
B Chen et al.
GENOMICS (2005)
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
M Hollingshead et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors
A Tannapfel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types
DR Gossett et al.
GYNECOLOGIC ONCOLOGY (2005)
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
P Workman
CANCER LETTERS (2004)
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms
DE Hansel et al.
CLINICAL CANCER RESEARCH (2004)
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours - A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
U Plockinger et al.
NEUROENDOCRINOLOGY (2004)
Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours
SS Guo et al.
JOURNAL OF ENDOCRINOLOGY (2003)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal et al.
NATURE (2003)
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells
RS Sippel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique
V Ehemann et al.
CANCER LETTERS (2003)
分享论文
